Graphene-based brain–computer interfaces are moving out of the lab and into U.S. clinical pathways, as INBRAIN partners with Mayo Clinic to validate a new materials-driven approach to neuromodulation.

A new entrant is forming in the brain–computer interface space with unusually deep capital, strong AI ties, and ambitions that may extend beyond medicine, adding a fresh dynamic to an already competitive neurotech field.

China is moving to industrialise brain–computer interfaces at a national scale, combining state funding, coordinated regulation, and parallel clinical development in an effort to compete with U.S.-led neurotech ecosystems.